MTOR and cancer: In agreement with the predictions resulting from our scoring system, the decrease in MLL2 expression, checked by quantitative PCR, resulted in increased mTORC1/2 activity (Figure 3C, right panel), which in turn suggests that these cancer cells may be more sensitive to mTOR pathway inhibitors.